Biotech Investor

Biotech investment is one of the exciting spaces in the stock market. The companies in this sector focus on clinical research and development of new drugs. There is tremendous potential for stocks to deliver outstanding gains when companies report positive trial data or when their drugs obtain FDA approval.

The challenge comes when identifying stocks with enormous potential, and tracking various stages of drug development and the regulatory process is not easy. For instance, pending clinical trial/regulatory catalysts, FDA and its regulatory processes, phases of drug development and scheduled dates of important events can be hard to track from multiple sources of data.

Subscribers benefit from RTTNews team’s more than 2 decades of experience in covering biotech and pharmaceutical industry. Not only that a dedicated team at RTTNews traces these companies and developments, we help you identify stocks in this sector with strong fundamentals. We also help subscribers keep abreast of important events at these companies including IPO, daily news and developments, etc.

However, RTTNews does not offer any buy/sell, entry/exit recommendations, or target price for any stocks that we feature.

As with any good investment, timing determines the level of return. As a subscriber, you will have access to all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions.

7-Day Free Trial (No Credit Card Required)

Biotech Investor Subscriber Benefits - RTTNews
  • doneLimited Time Offer $299 $199 /month after your 7-Day FREE Trial ends.
  • done Save 25% OR $149 /month with Annual Subscription.
  • done Unlimited Access across any device (mobile/desktop).
  • done Informative Email Alerts featuring important news.
  • done Unlimited ad-free access.
How subscribing to Biotech Investor will help you?
  • chevron_rightkeyboard_arrow_downFDA Calendar
    PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks. The FDA calendar covers large cap, mid cap, and small cap stocks with pending regulatory catalysts.
  • chevron_rightkeyboard_arrow_downNews Impacting Biotech Stocks
    This service covers corporate announcements or updates from healthcare companies listed on the Nasdaq as well as NYSE.
  • chevron_rightkeyboard_arrow_downBiotech Stocks On The Move
    Any major events or announcements made overnight or before and during the regular trading session can move the stock price. Sometimes, big stock movements are witnessed on no news. Our Biotech Stocks On The Move service helps subscribers gauge the direction of the stock.
  • chevron_rightkeyboard_arrow_downUpcoming Events
    Annual meetings organized by American Society Of Clinical Oncology (ASCO) and American Society of Hematology (ASH); investor conferences like Goldman Sachs Annual Biotech Symposium, Morgan Stanley Global Healthcare Conference, Piper Jaffray Healthcare Conference and J. P. Morgan Healthcare Conference, to name a few; and regulatory events like FDA/panel announcements. These events can move the healthcare stocks.
  • chevron_rightkeyboard_arrow_downInvesting in Biotech and Pharma
    RTT tracks and monitors hundreds of companies and potential market-moving events. These include pending new drug approvals, new FDA submissions, pending mid/early-stage clinical trial results, late-stage phase 3 clinical trial results, FDA advisory panel meetings and much more.
  • chevron_rightkeyboard_arrow_downIPO Alert
    This service provides news on upcoming healthcare IPOs.
  • chevron_rightkeyboard_arrow_downWeek Ahead In Pharma
    This weekly report lists events related to healthcare sector that could impact the stock price.
  • chevron_rightkeyboard_arrow_downIPO Lock-Up Expiration
    An IPO lock-up expiration, which typically occurs 180 days from the first day of trading, is often associated with stock sell-off.
  • chevron_rightkeyboard_arrow_downLong-Term Stocks
    In this service, you can access all information you need to know about stocks that have long-term investment potential.
  • chevron_rightkeyboard_arrow_downMake or Break Stocks
    This service alerts subscribers to stocks that have upcoming market-moving biotech events.
  • chevron_rightkeyboard_arrow_downThis Day That Year
    An overview of a company that has completed 1 year since its listing and the anticipated milestones.
Biotech Investor Recent Articles.
Synaptogenix - In Search Of A Drug That Reverses The Loss Of Brain Wiring
7/30/2021 10:26 AM ET

Shares of Synaptogenix Inc. (SNPX) have lost nearly 35% of their value over the past 5 trading days and trade around $7. Synaptogenix is a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases. The company's lead drug candidate is Bryostatin-1, a macrocyclic...

NextGen - In Good Health
7/30/2021 4:22 AM ET

NextGen Healthcare Inc. (NXGN), a health information technology company, which has started the fiscal year 2022 with strong momentum reflecting growing demand for its expansive offerings, has provided a rosy outlook for the year as it gains new clients. The company provides a range of software, services,...

Will Acer Therapeutics Hit Its Goals?
7/29/2021 6:21 AM ET

Shares of Acer Therapeutics Inc. (ACER) are up over 20% at $2.97 in pre-market trading Thursday, as the company gears up to submit its New Drug Application for ACER-001 this quarter. ACER-001, being developed in collaboration with Relief Therapeutics Holding AG, is intended for the treatment of Urea...

Writing Was Already On The Wall For Iterum, Shares Plunge
7/26/2021 8:46 AM ET

Shares of Iterum Therapeutics plc (ITRM) are down over 40% at $0.66 in pre-market trading Monday on a disappointing regulatory news related to lead drug candidate oral Sulopenem. Oral Sulopenem, proposed for the treatment of uncomplicated urinary tract infections (uUTI) in patients with quinolone...

pharma 033017 25jul21 lg
Week Ahead (Jul.26-30): INFI To Provide Update On Eganelisib Trials, Writing's On The Wall For ITRM?
7/25/2021 9:58 AM ET

In the trading week ended July 23, NeuroMetrix Inc. (NURO), which gained nearly 550%, was the star performer of the week, thanks to the double dose of good news. On July 20, the company announced that its Quell device received Breakthrough Designation from the FDA for treating the symptoms of fibromyalgia...

Alzamend Neuro Jumps 19% On Positive Toxicology Results From Its Alzheimer's Disease Therapy Study
7/23/2021 10:12 AM ET

Shares of Alzamend Neuro, Inc. (ALZN) are rising more than 19% Friday morning after the preclinical stage biopharmaceutical company announced positive toxicology results from the study of its Alzheimer's disease therapy, AL002. AL002 is a patented method using a mutant-peptide sensitized cell as a...

  • chevron_rightkeyboard_arrow_downFrequently Asked Questions
    Where do I login to access Biotech Investor / Premium Services ?

    Go to the following link to login and view your subscription
    In order to change payment details or personal details, login to the following link

    By what methods can I pay ?

    You can pay via Credit Card or Paypal account. Credit Card or Paypal account should be updated on or before the day your 7-Day FREE Trial ends.

    What is the subscription fees ?

    Limited Time Offer $299 $199 /month after your 7-Day FREE Trial ends.

    Is a Credit Card required for FREE Trial Subscription ?

    No, you can sign up for our 7-Day FREE Trial subscription without entering your credit card / payment details.

    My Email Address shows as already registered. How do I Sign up ?

    If you would like to subscribe using an already registered email address, kindly contact us.

    How do I subscribe for Annual Subscription ?

    If you would like to subscribe for annual subscription, kindly contact us.

  • chevron_rightkeyboard_arrow_downTerms & Conditions

    All of the free and premium services offered on are provided for information purposes only. None of the information or opinions expressed in any of our services should be construed as an offer or solicitation to buy or sell, or as an endorsement, recommendation of any securities, options, futures or funds. We are not investment advisors and we do not provide personalized advice. If you need personal advice, then you should seek the advice of a qualified investment advisor.

    All our services are designed to help you save time with your investment research. RTTNews does not warrant the reliability or completeness or accuracy of the Content found in our Services or its usefulness for any particular purpose. You are responsible for your own investment decisions. RTTNews will not be liable for any direct, indirect, incidental or any other type of loss or damages caused by a reader's reliance on information obtained on our site.

    Please read our Terms and Conditions of service for complete terms.